AGS-003 is being investigated in combination with well-established targeted drug therapies in a clinical trial called ADAPT (The Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma).

ADAPT is designed to enroll 450 patients with newly diagnosed mRCC.

Learn more at ClinicalTrials.gov